Peptide
Modified GRF 1-29
SaveA modified fragment of growth-hormone-releasing hormone (amino acids 1-29) with amino acid substitutions at positions 2, 8, 15, and 27 for improved stability. Often called CJC-1295 without DAC or Mod GRF.
Quick verdict
The most commonly used GHRH analog in peptide clinic protocols. Produces physiologic pulsatile GH release when combined with a GHRP.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Human pharmacologic data confirm GH release. Widely used in anti-aging protocols combined with ipamorelin. Formally identical to CJC-1295 without DAC.
Benefits
- Preserves physiologic pulsatile GH release
- Synergistic with GH secretagogues like ipamorelin
- Improved stability over native GRF 1-29
Dosage notes
Typical: 100 mcg subcutaneously at bedtime, combined with 100–300 mcg ipamorelin.
Side effects
- Flushing
- Headache
- Injection-site reactions
- Mild water retention
Who should be cautious
Not FDA-approved. Long-term effects of chronic GH-axis stimulation are uncertain.
What this page cannot tell you
Clinical outcome data are limited to GH/IGF-1 levels. Body composition and aging outcomes are not well studied.
Leaderboard scores
- Muscle38
- Recovery32
- Sleep22
- Longevity22
Write a review
Sign in to write a review.